Prognostic impact of β₂-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma

References

• Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983;52:1410–1416.
   PubMed Web of Science ®Google Scholar
• Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998;83:806–812.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tisses. Lyon: IARC Press; 2008.
   Google Scholar
• The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003;101:2489–2495.
   PubMed Web of Science ®Google Scholar
• Oh SY, Ryoo BY, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: analysis of 247 cases. Am J Hematol 2007;82:446–452.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007;63:245–256.
   PubMed Web of Science ®Google Scholar
• Suh C, Kim WS, Kim JS, et al. Review of the clinical research conducted by the Consortium for Improving Survival of Lymphoma of the Korean Society of Hematology Lymphoma Working Party. Blood Res 2013;48:171–177.
   Google Scholar
• Bertoni F, Zucca E. State-of-the-art therapeutics: marginal-zone lymphoma. J Clin Oncol 2005;23:6415–6420.
   PubMed Web of Science ®Google Scholar
• Oh SY, Suh C. Non-gastric marginal zone B-cell lymphoma in Korea: clinical features, treatment, and prognostic factors. Korean J Intern Med 2010;25:227–236.
   PubMedGoogle Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol 2013;24:857–877.
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma: prognostic value of disease dissemination. Oncologist 2006;11:285–291.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kwon HC, Kim WS, et al. Nongastric marginal zone B-cell lymphoma: a prognostic model from a retrospective multicenter study. Cancer Lett 2007;258:90–97.
   PubMed Web of Science ®Google Scholar
• Grey HM, Kubo RT, Colon SM, et al. The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med 1973;138:1608–1612.
   PubMed Web of Science ®Google Scholar
• Strominger JL. Human histocompatibility proteins. Immunol Rev 2002;185:69–77.
   PubMed Web of Science ®Google Scholar
• Constantinides IP, Pathouli C, Karvountzis G, et al. Serum beta 2 microglobulin in malignant lymphoproliferative disorders. Cancer 1985;55:2384–2389.
   PubMed Web of Science ®Google Scholar
• Yoo C, Yoon DH, Jo JC, et al. Prognostic impact of beta-2 microglobulin in patients with extranodal natural killer/T cell lymphoma. Ann Hematol 2014;93:995–1000.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Oh SY, Kim WS, Kim SJ, et al. Relapsed or refractory nongastric marginal zone B-cell lymphoma: multicenter retrospective analysis of 92 cases. Am J Hematol 2009;84:826–829.
   PubMed Web of Science ®Google Scholar
• Chronowski GM, Wilder RB, Tucker SL, et al. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease. Cancer 2002;95:2534–2538.
   PubMed Web of Science ®Google Scholar
• Shi C, Zhu Y, Su Y, et al. Beta2-microglobulin: emerging as a promising cancer therapeutic target. Drug Discov Today 2009;14:25–30.
   PubMed Web of Science ®Google Scholar
• Josson S, Nomura T, Lin JT, et al.β2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011;71: 2600–2610.
   Google Scholar
• Yang J, Zhang X, Wang J, et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 2007;110:3028–3035.
   PubMed Web of Science ®Google Scholar
• Yang J, Cao Y, Hong S, et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 2009;15:951–959.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar